18 December 2024
Vela Technologies plc
("Vela" or "the Company")
Interim results for the six months ended 30 September 2024
Vela Technologies plc (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, today announces its unaudited interim results for the six months ended 30 September 2024.
Overview
The last six months have continued to be challenging for the small-cap marketplace in the
During the period the Company reports a significant fair value loss on the investment portfolio, predominately arising from the fall in the share price of Conduit Pharmaceuticals Inc. ("Conduit"). As at 30 September 2024 Conduit's share price had fallen to
Vela made one new investment during the period, issuing shares valued at
Since the period-end Vela has made a further investment in Igraine Plc, an existing investee company, by way of a convertible loan note of no less than
Turning to the financials, the balance sheet has decreased, principally because of the revaluation of Conduit, with total assets amounting to
As at 30 September 2024, the investment portfolio comprises a total of 14 active investee companies and two legacy investments which have been valued at £nil for a number of years. 13 of the active investee companies are held as investments on the balance sheet having a fair value of
The Board looks forward to the remainder of the financial year ending 31 March 2025 with caution but ever mindful of potential new and follow-on investments in line with its investing policy. The Board will continue to update shareholders, in line with regulatory guidelines, via its quarterly investment updates and regulatory announcements. The directors would like to thank shareholders for their continued support.
Brent Fitzpatrick
Chairman
18 December 2024
Unaudited Statement of Comprehensive Income
for the six months ended 30 September 2024
|
|
(Unaudited) |
(Unaudited) |
(Audited) |
|
|
6 months ended |
6 months ended |
Year Ended |
|
|
30 September |
30 September |
31 March |
|
|
2024 |
2023 |
2024 |
|
Notes |
£'000 |
£'000 |
£'000 |
|
|
|
|
|
Revenue |
|
- |
- |
- |
|
|
|
|
|
Fair value movements |
|
|
|
|
- on derivatives |
|
- |
(55) |
- |
- on financial asset |
|
- |
1,250 |
- |
- on investments |
|
(2,603) |
(518) |
(357) |
Net (deficit) / surplus arising from fair value movements |
|
(2,603) |
677 |
(357) |
Administrative expenses |
|
(127) |
(181) |
(443) |
Operating (loss) / profit |
|
(2,742) |
496 |
(800) |
Finance income |
|
6 |
6 |
23 |
(Loss) / profit before tax |
|
(2,736) |
502 |
(777) |
Income tax |
|
- |
- |
- |
(Loss) / profit / after tax |
|
(2,736) |
502 |
(777) |
|
|
|
|
|
Other comprehensive income for the year |
|
- |
- |
- |
|
|
|
|
|
Total comprehensive (loss) / profit |
|
(2,736) |
502 |
(777) |
Attributable to: |
|
|
|
|
Equity holders of the company |
|
(2,736) |
502 |
(777) |
(Loss) / profit per share |
|
|
|
|
Basic and diluted (loss) / profit per share (pence) |
4 |
(0.016) |
0.0031 |
(0.0050) |
Unaudited Balance Sheet
as at 30 September 2024
|
|
(Unaudited) 30 September |
(Unaudited) 30 September |
(Audited) 31 March |
|
|
2024 |
2023 |
2024 |
|
Notes |
£'000 |
£'000 |
£'000 |
Non-current assets |
|
|
|
|
Investments |
5 |
2,652 |
2,789 |
5,487 |
Trade and other receivables |
6 |
718 |
4,704 |
718 |
Total non-current assets |
|
3,370 |
7,493 |
6,205 |
|
|
|
|
|
Current assets |
|
|
|
|
Trade and other receivables |
|
300 |
- |
- |
Derivative financial instruments |
7 |
32 |
18 |
32 |
Cash and cash equivalents |
|
103 |
31 |
54 |
Total current assets |
|
435 |
49 |
86 |
Total assets |
|
3,805 |
7,542 |
6,291 |
|
|
|
|
|
Equity and liabilities |
|
|
|
|
Equity |
|
|
|
|
Called-up share capital |
8 |
3,563 |
3,291 |
3,320 |
Share premium reserve |
|
7,672 |
7,594 |
7,615 |
Share-based payment reserve |
|
6 |
46 |
6 |
Retained earnings |
|
(7,439) |
(3,424) |
(4,703) |
Total equity |
|
3,802 |
7,507 |
6,238 |
Current liabilities |
|
|
|
|
Trade and other payables |
|
3 |
35 |
53 |
Total current liabilities |
|
3 |
35 |
53 |
Total equity and liabilities |
|
3,805 |
7,542 |
6,291 |
Unaudited Cashflow Statement
for the six months ended 30 September 2024
|
(Unaudited) 6 months ended |
(Unaudited) 6 months ended |
(Audited) year ended |
|
30 September |
30 September |
31 March |
|
2024 |
2023 |
2024 |
|
£'000 |
£'000 |
£'000 |
Operating activities |
|
|
|
Loss / profit before tax |
(2,736) |
502 |
(777) |
Share based payment |
- |
- |
- |
Fair value movements on investments |
2,603 |
(732) |
357 |
Fair value movements on derivative instruments |
- |
55 |
- |
Finance income |
- |
(6) |
(23) |
(Decrease) / increase in payables |
(50) |
2 |
15 |
Total cash flow from operating activities |
(183) |
(179) |
(428) |
Investing activities |
|
|
|
Interest received |
- |
- |
14 |
Proceeds from sale of investments |
232 |
136 |
344 |
Payment for put option |
- |
(400) |
- |
Purchase of investments |
- |
(250) |
(650) |
Total cash flow from investing activities |
232 |
(514) |
(292) |
Financing activities |
|
|
|
Proceeds from the issue of ordinary shares |
- |
- |
50 |
Total cash flow from financing activities |
- |
- |
50 |
|
|
|
|
Net increase / (decrease) in cash and cash equivalents |
49 |
(693) |
(670) |
Cash and cash equivalents at start of year/period |
54 |
724 |
724 |
Cash and cash equivalents at the end of the year/period |
103 |
31 |
54 |
Cash and cash equivalents comprise: |
|
|
|
Cash at bank |
103 |
31 |
54 |
Cash and cash equivalents at end of year / period |
103 |
31 |
54 |
Unaudited Statement of Changes in Equity
for the six months ended 30 September 2024
|
Share capital |
Share Premium |
Share Option Reserve |
Retained Earnings |
Total Equity |
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
Balance at 1 April 2024 |
3,320 |
7,615 |
6 |
(4,703) |
6,238 |
Share issue |
243 |
57 |
- |
- |
300 |
Loss and total comprehensive income for the period |
- |
- |
- |
(2,736) |
(2,736) |
Balance at 30 September 2024 |
3,563 |
7,672 |
6 |
(7,439) |
3,802 |
|
|
|
|
|
|
Balance at 1 April 2023 |
3,291 |
7,594 |
46 |
(3,926) |
7,005 |
Profit and total comprehensive income for the period |
- |
- |
- |
502 |
502 |
Balance at 30 September 2023 |
3,291 |
7,594 |
46 |
(3,424) |
7,507 |
|
|
|
|
|
|
Balance at 1 April 2023 |
3,291 |
7,594 |
46 |
(3,926) |
7,005 |
Share-based payment |
- |
- |
(40) |
- |
(40) |
Share issue |
29 |
21 |
- |
- |
50 |
Loss and total comprehensive income for the period |
- |
- |
- |
(777) |
(777) |
Balance at 31 March 2024 |
3,320 |
7,615 |
6 |
(4,703) |
6,238 |
Notes to the Interim Accounts
for the six months ended 30 September 2024
1. General information
Vela Technologies plc is a company incorporated in the
These unaudited condensed interim financial statements for the six months ended 30 September 2024 have been prepared in accordance with International Financial Reporting Standards (IFRS) and IAS 34 "Interim Financial Reporting" as adopted by the European Union and do not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. This condensed set of financial statements has been prepared applying the accounting policies that were applied in the preparation of the Company's published financial statements for the year ended 31 March 2024 and are presented in pounds sterling.
The comparative figures for the financial year ended 31 March 2024 have been extracted from the Company's statutory accounts which have been delivered to the Registrar of Companies and reported on by the Company's Auditors. Their report was unqualified and contained no statement under section 298 (2) or (3) of the Companies Act 2006.
2. Changes in accounting policy
The assessment of new standards, amendments and interpretations issued but not effective are not anticipated to have a material impact on the interim financial statements.
3. Going concern
The Directors have considered the Company's activities, together with the factors likely to affect its future development and performance, the financial position of the Company, and its cash flows and liquidity position, taking account of the current market conditions. This review has demonstrated that the Company shall continue to operate within its own resources.
The Directors believe that the Company is well placed to manage its business risks successfully and that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they consider it appropriate to adopt the going concern basis in preparing these condensed financial statements.
4. (Loss) / profit per share
(Loss) / profit per share has been calculated on a loss of
|
6 months ended 30 September 2024 |
6 months ended 30 September 2023 |
Year ended 31 March 2024 |
(Loss) / profit (£'000) |
(2,736) |
502 |
(777) |
(Loss) / earnings per share (pence) |
(0.016) |
0.0031 |
(0.005) |
5. Investments
|
Other Investments £'000s |
Fair value at 1 April 2024 |
5,487 |
Additions during the period |
- |
Disposals during the period |
(232) |
Current period fair value movement charged to profit or loss |
(2,603) |
Fair value at 30 September 2024 |
2,652 |
Investment in Hamak Gold Limited and issuance of share capital
In July 2024 the Company entered into an unsecured convertible loan note instrument with Hamak Gold Limited ("Hamak"), the
Part disposal of shares in EnSilica plc
During the period the Company disposed of an aggregate of 160,000 shares at an average price of 59p per share, generating gross proceeds of
Part disposal of shares in Skillcast Group plc
During the period the Company disposed of a total of 100,000 shares at an average price of 44p per share, generating gross proceeds of
Disposal of holding in MTI Wireless Edge Ltd
In September 2024 the Company disposed of its entire holding of 200,000 shares at a price of 46p per share, generating gross proceeds of
6. Trade and other receivables - non-current
|
30 September |
30 September |
31 March |
|
2024 |
2023 |
2024 |
|
£'000 |
£'000 |
£'000 |
Loan due from Bixx Tech Limited |
718 |
704 |
718 |
Other financial asset |
- |
4,000 |
- |
|
718 |
4,704 |
718 |
Loan due from Bixx Tech Limited
The loan represents the consideration receivable for the disposal of certain investment assets in August 2020. The total consideration receivable is
Under the terms of the loan agreement, the Company has provided an undertaking to distribute a sum equal to any repayment of the loan to the holders of the Special Deferred Shares. Details of these arrangements are set out in the audited financial statements for the year ended 31 March 2024. This distribution will be by way of a dividend declared on the Special Deferred Shares ("the Special Dividend"). In the event that insufficient distributable reserves exist at the end of the seven-year loan term, the repayment of the loan will be deferred for a further year. This deferral will continue until such a time as the Company has sufficient distributable reserves to be able to pay the Special Dividend.
Other financial asset - Investment in St George Street Capital
On 20 October 2020, the Company entered into a contract with St George Street Capital ("SGSC") for an 8% economic interest in the potential future commercialisation of SGSC's asset to treat individuals with diabetes who are suffering with COVID-19 ("the Asset"). The consideration payable under the terms of the contract was
In April 2023, the Company announced that it had entered into a put option agreement to give the Company the right, but not the obligation, to sell its economic interest in the commercialisation of the Covid-19 application of AZD1656 in return for shares in Conduit Pharmaceuticals Limited ("Conduit"). The Option was granted by Conduit and its prospective parent company, Murphy Canyon Acquisition Corp, a Company listed on NASDAQ.
On 1 December 2023, Vela exercised the put option to sell its economic interest in return for shares in Conduit. Under the terms of the option agreement Vela received 1,015,760 new shares of authorised common stock of par value
7. Derivative financial instruments
|
30 September |
30 September |
31 March |
|
2024 |
2023 |
2024 |
|
£'000 |
£'000 |
£'000 |
Warrants |
32 |
18 |
32 |
|
32 |
18 |
32 |
|
|
|
|
The Company holds warrants providing it with the right to acquire additional shares in certain of its investee companies at a fixed price in the future, should the directors decide to exercise them. The warrants have been recognised as an asset at fair value, which has been calculated using an appropriate option pricing model.
8. Share capital
Allotted, called up and fully paid capital |
30 September 2024 |
30 September 2023 |
31 March 2024 |
18,970,695,255 Ordinary Shares of |
1,897 |
1,625 |
1,654 |
1,748,943,717 Deferred Shares of |
1,399 |
1,399 |
1,399 |
2,665,610,370 Special Deferred Shares of |
267 |
267 |
267 |
|
3,563 |
3,291 |
3,320 |
On 22 July 2024, 2,424,242,242 Ordinary 0.01 Shares were issued at a deemed issue price of
The number of shares in issue at 30 September 2024 were 18,970,695,255 (30 September 2023 and 31 March 2024: 16,546,452,831).
9. Financial instruments
The Company is required to report the category of fair value measurements used in determining the value of its investments, to be disclosed by the source of its inputs, using a three-level hierarchy. There have been no transfers between Levels in the fair value hierarchy.
Quoted market prices in active markets - "Level 1"
Inputs to Level 1 fair values are quoted prices in active markets for identical assets. An active market is one in which transactions occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The Company has eleven (30 September 2023: twelve; 31 March 2024: twelve) investments classified in this category. The aggregate historic cost of these investments is
Valued using models with significant observable market parameters - "Level 2"
Inputs to Level 2 fair values are inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly. The Company has two (30 September 2023: two; 31 March 2024: two) unquoted investments classified in this category. The historic cost of these investments is
Valued using models with significant unobservable market parameters - "Level 3"
The Company has two (30 September 2023: two; 31 March 2024: two) legacy investments that are held at an aggregate carrying value of £nil at 30 September 2024 (30 September 2023: £nil; 31 March 2024: £nil) because they appear to be inactive, based on the information held by Vela. As at 30 September 2024 the historical cost of this investment amounted to
The Company also holds a convertible loan note at a fair value of
10. Related party transactions
During the period the Company entered into the following related party transactions. All transactions were made on an arm's length basis:
Ocean Park Developments Limited
Brent Fitzpatrick, non-executive chairman, is also a director of Ocean Park Developments Limited. During the period the Company paid
11. Principal risks and uncertainties
Principal risks and uncertainties are set out in the annual financial statements within the directors' report and also in note 14 to those financial statements and are reviewed on an on-going basis.
The Board provides leadership within a framework of appropriate and effective controls. The Board has set up, operates and monitors the corporate governance values of the Company, and has overall responsibility for setting the Company's strategic aims, defining the business objective, managing the financial and operational resources of the Company and reviewing the performance of the officers and management of the Company's business both prior to and following an acquisition.
There have been no significant changes in the first six months of the financial year to the principal risks and uncertainties as set out in the 31 March 2024 Annual Report and Accounts.
12. Board approval
These interim results were approved by the Board of Vela Technologies plc on 18 December 2024.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.